CompletedNot Applicable

Retention of Telescopic Versus Locator Attachments

Egypt40 participantsStarted 2021-04-01

Plain-language summary

Forty patients ( 24female and16 male )with completely edentulous maxilla and mandible . All patients received implant supported mandibular and maxillary overdentures. The patients were randomly divided into two groups according to attachments retaining Max IOD that supported by four axial implants in maxilla . The TA was used to retain group I (GrI) MaxIOD , while that of group II (Gr II) was retained by LA. MaxIOD retention and MBL(vertical and horizontal) around implants of both groups was recorded at time of insertion (R0) ,then twelve(R12)and (R24) months following insertion of the prosthesis.

Who can participate

Age range

40 Years – 75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * have sufficient bone volume(classes IV to VI, Cawood and Howell) and quality (classes I to III, Lekholm and Zarb) * be fully edentulous for at least 1 year and did not have an American Society of Anesthesiologists score (ASA) of IV or higher. * be with Angle Class I maxillo- mandibular relationship * have Adequate zone of keratinized attached mucosa \>5mm over the crest of the upper and lower ridge * have adequate inter-arch space (22 mm) as determined by the mounted casts carrying the patient upper and lower complete dentures . Exclusion Criteria: * Any medical disorders that could complicate the surgical phase or affect osseointegration as osteoporosis, uncontrolled diabetes and hypertension * Smoking; - Former radiotherapy in the head and neck region * Former pre-prosthetic surgery or loss of implants in the maxilla * Patients with para-functional habits (as clenching or bruxism) * Hard tissue augmentation / grafting.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Retention

Timeframe: 1 month, 12 months, and 24 months

Trial details

NCT IDNCT06349525

SponsorDelta University for Science and Technology

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-07-05

View on ClinicalTrials.gov More Jaw, Edentulous trials